Myriad Genetics Inc (MYGN)
- Sector
- Biotechnology
- Last price
- $5.54
- As of
Kresmion compiles this page from MYGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MYRIAD GENETICS INC (MYGN): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full MYGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MYGN on one page. Preview it with sample data, then open it live with a free account.
Preview the MYGN dossierActive events for MYGN
- mediumEarnings above estimates
Q3-2026: Beat consensus by 46.1%, EPS $-0.11 vs $-0.204 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 87% of MYGN (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 80% of MYGN (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +860% to MYGN (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 75% of MYGN (2026Q2)
FREE, NO ACCOUNT
Every event on MYGN, as it fires
You are seeing 5 of 11 events recorded on MYGN since 2026-06-02.
The five above landed across 2 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
MYGN positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 62855J104 · 2026Q3 | $1.1M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MYGN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on MYGN
MYGN against its peers
MYGN's operating margin of -47.0% ranks in the 88th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | MYGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 825M USD | 7.3M USD | 97 | 15 |
| Gross margin | 69.9% | n/a | n/a | 3 |
| Operating margin | -47.0% | -387.5% | 88 | 12 |
| Net margin | -44.4% | -239.0% | 81 | 12 |
| Return on equity | -99.4% | -47.0% | 20 | 21 |
| 1 year | -13.5% | 5.5% | 25 | 21 |
Peers (22): ZVRA, VALN, CAPR, EPRX, CBIO, SANA, ENTX, FTH, OBIO, SRZN, RGNX, NGNE, MNPR, GERN, CLYM, OVID, CGEM, ABUS, DMAC, STTK, WVE, GYRE. Left out: SLBT (no annual filing), IAM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (MYGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in MYGN on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MYGN in the last 180 days.
Upstream: SEC EDGAR filings for MYGN
Kresmion, "MYRIAD GENETICS INC (MYGN) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/MYGN. Upstream data: SEC EDGAR filings for MYGN.
Link to this data (HTML):
<a href="https://kresmion.com/research/MYGN">MYRIAD GENETICS INC (MYGN) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow MYGN on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MYGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.